BioSpace News Archive

T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced financial results for the second quarter ended June 30, 2020.

10x Genomics, Inc. reported financial results for the second quarter ended June 30, 2020.

Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today it is launching a Named Patient Program for its non-opioid bone metastases pain palliation drug, Strontium89 (Strontium Chloride Sr-89 Injection, USP).

FDA has cleared MagVenture TMS Therapy® for adjunct treatment of Obsessive-Compulsive Disorder (OCD)

Western Digital (NASDAQ: WDC) today announced that the Institut du Cerveau et de la Moelle Épinière (ICM Brain and Spine Institute), an international brain and spinal cord research center, selected Western Digital to update its storage infrastructure with the extremely fast, efficient and flexible OpenFlex open composable platform.

Scioto Biosciences announced today the closing of a strategic investment of up to $26.5M from Genome & Company and other investors to join in an upcoming tranche.

General Automation Lab Technologies (GALT) and CosmosID today announced the launch of a new scientific challenge program to award a complete microbiome characterization workflow to one project addressing the role of the microbiome in human disease

Sun BioPharma, Inc. (OTCQB: SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with pancreatic cancer, today provides a business update and reports financial results for the quarter ended June 30, 2020.

SyntheticMR announced today that their imaging software SyMRI is compatible with additional scanners from Siemens Healthineers on the US market, including 1.5T scanners such as MAGNETOM Altea, Sola and Sola Fit, as well as 3T scanners such as MAGNETOM Skyra and Prisma

Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced today a positive outcome of an interim futility review for the HopES Sarcoma Phase II clinical trial that is evaluating TYME’s lead cancer metabolism-based candidate,